Physician profile
David B Hall
NPI 1518931518
$2,665.28
in general payments reported to CMS, 2019-2025
28 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $381 · 2021: $431 · 2022: $389 · 2023: $508 · 2024: $329 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.86 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $282.63 | 2019-2025 | |
| Lilly USA, LLC | $224.21 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $217.00 | 2021-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $199.23 | 2020 | |
| Glaxosmithkline, LLC. | $165.14 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $139.92 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $113.32 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.57 | 2023 | |
| Xeris Pharmaceuticals, INC. | $68.22 | 2023-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $63.46 | 2021-2023 | |
| Daiichi Sankyo INC. | $56.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.02 | 2022-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.91 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.52 | 2022 | |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| Recordati_rare_diseases_inc. | $22.78 | 2023 | Panhematin |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $19.63 | 2020 | |
| Corcept Therapeutics | $19.28 | 2024 | Korlym |
| Almatica Pharma LLC | $16.77 | 2022 | |
| Pulmonx Corporation | $16.26 | 2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Astellas Pharma US INC | $15.82 | 2021 | |
| Sumitomo Pharma America, INC. | $14.54 | 2023 | Gemtesa |
| Radius Health, INC. | $14.49 | 2021 | |
| Eisai INC. | $14.30 | 2021 | |
| Dexcom, INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.